High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

Hannah Yang,Beodeul Kang,Yeonjung Ha,Sung Hwan Lee,Ilhwan Kim,Hyeyeong Kim,Won Suk Lee,Gwangil Kim,Sanghoon Jung,Sun Young Rha,Vincent E Gaillard,Jaekyung Cheon,Chan Kim,Hong Jae Chon

JHEP reports : innovation in hepatology（2023）

引用 8|浏览41

暂无评分

摘要

Although patients with hepatocellular carcinoma who respond to treatment with atezolizumab and bevacizumab exhibit favourable clinical outcomes, a fraction of these still experience primary resistance. We found that high baseline serum levels of IL-6 correlate with poor clinical outcomes and impaired T-cell response in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab.

查看译文

关键词

AFP, alpha-foetoprotein,Ate/Bev, atezolizumab and bevacizumab,Atezolizumab,BCLC, Barcelona Clinic Liver Cancer,Bevacizumab,CB6m, clinical benefit 6 months,CONSORT, Consolidated Standards of Reporting Trials,CR, complete response,CRAFITY, C-reactive protein and AFP in immunotherapy,CTLA-4, cytotoxic T-lymphocyte-associated protein 4,DC, dendritic cell,ECOG, Eastern Cooperative Oncology Group,FFPE, formalin-fixed paraffin-embedded,HCC, hepatocellular carcinoma,HR, hazard ratio,Hepatocellular carcinoma,IFN-γ, interferon-γ,IL-6,Immunotherapy,MDSC, myeloid-derived suppressor cell,MSI, microsatellite instability,MVI, macrovascular invasion,ORR, objective response rate,OS, overall survival,PBMC, peripheral blood mononuclear cell,PD, progressive disease,PD-1, programmed-death-1,PD-L1, programmed-death ligand-1,PFS, progression-free survival,PR, partial response,RECIST, Response Evaluation Criteria in Solid Tumours,SD, stable disease,TME, tumour microenvironment,TNF-α, tumour necrosis factor-α,VEGF, vascular endothelial growth factor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要